mfn-cus-financial-reports-2016 archive - CombiGene

Skip to content

About CombiGene
Projects
The Market
Organization
Investors
Media
Contact
- Contact us
- Downloads

About CombiGene
Projects
The Market
Organization
Investors
Media
Contact
- Contact us
- Downloads

SV

News Tag: mfn-cus-financial-reports-2016

CombiGene Annual Report 2016

April 18, 2017

Se årsredovisning >>

About CombiGene AB

CombiGene’s vision is to provide patients affected by severe diseases with the prospect of a better life through gene therapy and other forms of advanced treatments.
Our business has three focus areas: sourcing of new and promising assets, development of these assets to proof of concept under our management and expertise, and outlicensing of the assets to a strategic partner for continued development and commercialization. Revenue is achieved through milestone payments and royalties.

The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market. The company’s Certified Advisor is FNCA Sweden AB.

CombiGene AB
Agavägen 52A
SE-181 55 Lidingö
Sweden

info@combigene.com

Follow what's happening at CombiGene, subscribe to our newsletter.

Our privacy policy

Linkedin Twitter Facebook-f

© 2023 CombiGene AB | All rights reserved